Let’s Get Social with Nóri!

31/10/2019

Sales person, communication expert and Head of Omixon’s Marketing Team – she is the always positive and smiley Nóri who answers questions this time. What is your profession? What did you study originally? I’m an economist and a marketing communications expert by degree, but I was always involved in business...

NGS rEvolution – Minimal Residual Disease Detection <=> Maximal Relapse Prevention

29/10/2019

Development of techniques in molecular biology over the last couple of years has not influenced only rEvolution (revolution + evolution) in HLA typing but also in other segments of onco-diagnostics and transplant medicine. Evaluation and implementation of Next Generation Sequencing (NGS) technology in Minimal Residual Disease (MRD) detection and monitoring...

Omixon to Launch OmniType – Join Our Early Access Program!

21/10/2019

Omixon is gearing up to launch a Multiplex HLA typing product for use on Illumina sequencing platforms. This new product line – OmniType – is expected to be a best-in-class product featuring locus multiplexing and short library preparation. The requirements for its development came both from you in the HLA...

Interview with Gergely Tölgyesi, Molecular Biologist at Omixon

30/09/2019

The following interview is part of the Omixon interview series that we are conducting with Key Opinion Leaders, Experts and Business Managers at Omixon. This time Gergely Tölgyesi, Technical Lead of Assay R&D answers questions related to his professional background, history of joining the Omixon team and shares secrets about...

Welcome to the Team, Elmar!

30/09/2019

We are proud to announce and welcome Elmar Schilling, who has recently joined our company as the Chief Technology Officer of Omixon. Elmar was born and raised in Bavaria, the southern part of Germany. He graduated in Molecular Biology and completed his PhD studies in the field of Epigenetics at Regensburg University ...